Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 451 Show results per page	View Search Criteria \| Help With Results

Last Modified: 2/26/2008


1.		Phase II/III Randomized Study of EM/VBL vs EM for Metastatic Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				any age								EORTC-30944

Last Modified: 3/18/2008 First Published: 4/1/2001


2.		Phase II/III Randomized Study of Gemcitabine and Carboplatin Versus Methotrexate, Carboplatin, and Vinblastine in Previously Untreated Patients With Transitional Cell Cancer of the Urothelium Who are Ineligible for Cisplatin-Based Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other				EORTC-GU-30986 NCT00014274


3.		Phase II-III Chemotherapy with BLEO/DTIC/VBL/ADR/PRED or NM/VCR/PCB/PRED Plus Radiotherapy for Advanced Hodgkin's Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								DFCI-75100

Last Modified: 5/23/2007


4.		Phase II/III Chemotherapy with MVP (MITO/VBL/CACP) vs CHIP vs CBDCA vs VBL/CACP vs MVP-CAMP (MITO/VBL/CACP/CTX/ADR/MTX/PCB) in Patients with Metastatic (Stage III) non-Small Cell Bronchogenic Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				EST-1583 EST-1583


5.		Phase II/III Comparison of VBL/Single-Dose DHAD vs VBL/5-Day DHAD for Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				15 and over								MDA-MBDT-8085

Last Modified: 2/15/2006


6.		Phase II/III Master Protocol for Chemotherapy with DTIC/ACT-D vs CACP/VBL/BLEO vs Phase II Agent with or without Prophylactic Cranial Radiotherapy for Disseminated Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI				SWOG-8107 SWOG-8107

Last Modified: 5/3/2007


7.		Phase II/III Pilot Combination Chemotherapy with VBL, VP-16, and CTX plus Autologous Bone Marrow Transplant with or without Radiotherapy in Patients with Selected Malignant Solid Tumors and Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 55								UCLA-81107522 NCI-V83-0180

Last Modified: 2/1/1988


8.		Phase II/III Randomized Comparison of M-VAC (MTX/VBL/ADR/CACP) Alone vs Combined with Radiotherapy Following Transurethral Tumor Resection in Patients with Locally Advanced Transitional Cell Carcinoma of the Bladder (Summary Last Modified 02/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				any age				NCI				MSKCC-87102 NCI-T87-0235C, T87-0235

Last Modified: 6/1/1996


9.		Phase III Randomized Study of VBL vs VBL/EM for Metastatic Hormone-Refractory Prostate Cancer (Summary Last Modified 06/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Other				HOG-GU93-1 NCI-V94-0424

Last Modified: 10/1/2007 First Published: 4/1/1994


10.		Phase III Randomized Study of Radiotherapy With or Without Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Versus ABVD Only in Patients With Stage I-IIA Hodgkin's Disease

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 and over				Other				CAN-NCIC-HD6 E-JHD06, NCI-V94-0427, NCT00002561, HD6, JHD06

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute